

ASX Announcement
13 Sep 2023

emyria

A clinical stage biotech informed by patient experience.
Tackling unmet needs in neuroscience and mental health.

PaxCentre

Emyria Completes Acquisition of the Pax Centre

Emyria Limited (ASX: EMD) ("Emyria", or the "Company") a clinical services and drug development company focussed on mental health is pleased to confirm the successful acquisition of Mind Body Consulting Pty Ltd, trading as the Pax Centre, after both parties have satisfied the Conditions Precedent disclosed to the market on 3rd July 2023. [1]

The strategic acquisition, valued at $1.7 million and executed through a combination of shares and cash, marks the commencement of Emyria's growth strategy and commitment to redefine mental health care delivery and drug development in Australia and beyond.

Key benefits of the acquisition:

- **Psychedelic-assisted Therapy Leadership:** The combined knowledge and infrastructure of Emyria and the Pax Centre strengthen Emyria's leadership position in the emerging field of psychedelic-assisted therapies ('PAT'). By supporting a unique wraparound care model, Emyria ensures quality care before, during, and after PAT which positions Emyria favorably with payers, referring doctors and collaborators.
- **Increased Clinical Revenue Potential:** With a more diverse team of health professionals and expanded clinical capabilities, Emyria can increase its range of services, patient outcomes and potential revenue streams allowing for greater reinvestment into Emyria's own research and drug development initiatives.
- **Enhanced Data Collection:** By serving a more diverse patient base, Emyria improves its capacity to capture robust and comprehensive clinical data using its advanced tools. A richer dataset further supports Emyria's drug development programs and innovative clinical service strategies.


As a result of the acquisition, Emyria is well advanced to deliver psychedelic-assisted therapy to suitably qualified patients having:

- Secured a supply of patient-ready MDMA [2]
- Trained a diverse team of therapists and clinicians [3]
- Obtained ethics-approval for our MDMA-assisted therapy for PTSD program [4]
- Established an advanced patient data registry [5]

Emyria is further extending its suite of offerings by developing care models for ketamine-, and psilocybin-assisted therapies [6] and Authorised Prescriber applications for Emyria's psychiatrists have been submitted.

Dr. Michael Winlo, CEO of Emyria, commented: *"This acquisition combines the Pax Centre's expertise in psychological trauma care and specialised facilities with Emyria's clinical, Real-World Data and drug development strengths and marks the commencement of Emyria's growth strategy and commitment to redefine mental health care delivery and drug development in Australia and beyond."*

RECENT TRACTION & UPCOMING MILESTONES



References:

1. See ASX release 03 July 2023
2. See ASX release 13 February 2023
3. See ASX release 07 March 2023
4. See ASX release 08 June 2023
5. See ASX release 07 October 2021
6. See ASX release 08 August 2023

This release has been approved by the Managing Director of Emyria.

FOR FURTHER INFORMATION

Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com

Sara Polanski
Communication Manager
+61 (0) 404 110 099
media@emyria.com

Sufian Ahmad
Corporate Advisor
+61 (0) 412 316 162
info@62capital.com.au

ABOUT EMYRIA | emyria.com

- **Emyria Limited** is a clinical services and drug development company with a focus on revolutionising patient outcomes in neuroscience and mental health via:
  - **Clinical Service Delivery:** With Emerald Clinics, and the recent acquisition of the Pax Centre, a leading psychological trauma center, Emyria delivers evidence-based and emerging therapies for mental health and other unmet needs.
  - **Proprietary Real-World Data (RWD):** Through its advanced data platform powered by Palantir, Emyria collects robust and ethically-sourced Real-World Data to improve its care models and support its distinct therapy and drug development initiatives.
  - **Drug Discovery & Development:** Guided by its RWD, Emyria is developing several proprietary Ultra-Pure cannabinoid dose forms and advancing them towards registration. In parallel, we are establishing one of the world's largest libraries of MDMA-like compounds in partnership with the University of Western Australia.

generates

informs

EMYRIA'S INTERACTIVE INVESTOR HUB
Investorhub.emyria.com Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.

ABOUT The Pax Centre | paxcentre.com.au

The Pax Centre specialises in treating individuals grappling with the psychological impacts of traumatic experiences. Our treatment approach is highly personalised, addressing a wide range of mental health issues, from PTSD and depression to anxiety disorders and substance abuse, often stemming from various life traumas.

Complex trauma, characterised by repeated, relational traumatic events often occurring during developmental stages, requires specialised attention due to its pervasive and lasting impact. In these cases, The Pax Centre prioritises early diagnosis and evidence-based treatments.

We also focus on proactive strategies for health expansion and personal growth, empowering our clients with skills and tools to improve wellbeing and performance. At the Pax Centre, we believe in transforming lives through focused, evidence-based mental health care

ABOUT Emerald Clinics | emeraldclinics.com.au

Emerald Clinics is an Australian-based, patient-centric clinical service specialising in providing treatments for patients with complex and chronic conditions, where traditional therapies might not have yielded satisfactory results.

Leveraging our deep expertise with unregistered medicines, such as cannabinoids, we strive to pioneer and personalise care for our patients. Our robust, ethically-sourced data collection methods underpin our commitment to improving patient outcomes and advancing healthcare innovation.

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.